Greer Massey, PhD, chief scientific officer at Molecular Designs, shares insights on how labs are affected by the rule’s reversal and how they can prepare for future regulatory changes.
The agency signals intent to withdraw final rule extending regulatory authority to LDTs following federal court ruling that vacated the regulation.
The company's be.well platform can detect seasonal influenza A and B as well as avian influenza A(H5) in humans within 45 minutes at the point of care.
CURECA and STAgora technologies aim to eliminate manual intervention in molecular testing workflows and provide actionable diagnostic data insights.
The eQUANT System delivers antibiotic susceptibility testing results in 70 minutes, cutting turnaround time by up to 24 hours.
